Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Poxel SA
< Previous
1
2
Next >
Poxel Announces the Publication of Two Preclinical Articles on X-Linked Adrenoleukodystrophy for PXL065 and PXL770
July 05, 2022
From
Poxel SA
Via
Business Wire
Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting
June 22, 2022
From
POXEL SA
Via
Business Wire
Poxel Announces New Solid Form Patent for PXL065 that Provides Additional Protection through 2041
June 09, 2022
From
Poxel SA
Via
Business Wire
Poxel Announces its Participation in Upcoming Investor and Scientific Conferences
May 31, 2022
From
Poxel SA
Via
Business Wire
Poxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2022
May 17, 2022
From
Poxel SA
Via
Business Wire
Poxel Announces PXL065 and PXL770 Granted Orphan Drug Designation from the U.S. FDA for X-Linked Adrenoleukodystrophy
May 17, 2022
From
Poxel SA
Via
Business Wire
Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2022
May 13, 2022
From
Poxel SA
Via
Business Wire
Poxel Announces Availability of Its 2021 Universal Registration Document
May 04, 2022
From
POXEL SA
Via
Business Wire
Poxel Announces Its Participation in Upcoming Scientific Conferences
April 25, 2022
From
Poxel SA
Via
Business Wire
Poxel Announces PXL770 Awarded FDA Fast Track Designation for X-linked Adrenoleukodystrophy
April 11, 2022
From
Poxel SA
Via
Business Wire
Poxel Reports Financial Results for Full Year 2021 and Provides Corporate Update
March 22, 2022
From
POXEL SA
Via
Business Wire
Poxel to Report Financial Results for Full Year 2021 and Host Webcast Call on March 22, 2022
March 15, 2022
From
Poxel SA
Via
Business Wire
Poxel Announces PXL065 Granted FDA Fast Track Designation for X-linked Adrenoleukodystrophy
February 16, 2022
From
Poxel SA
Via
Business Wire
Poxel Reports Financial Update for Cash and Revenue for the Full Year 2021 and Provides Corporate Update
February 16, 2022
From
Poxel SA
Via
Business Wire
Poxel Announces Financial Calendar for 2022
January 04, 2022
From
POXEL SA
Via
Business Wire
Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in January 2022
December 14, 2021
From
Poxel SA
Via
Business Wire
Poxel Announces the Formation of its Scientific Advisory Board for Rare Metabolic Diseases
December 06, 2021
From
Poxel SA
Via
Business Wire
Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in November
November 03, 2021
From
Poxel SA
Via
Business Wire
Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2021
October 20, 2021
From
Poxel SA
Via
Business Wire
Poxel Announces its Participation at Investor Conferences in October 2021
September 30, 2021
From
POXEL SA
Via
Business Wire
Poxel Announces its Participation at Upcoming Scientific Conferences Related to Adrenoleukodystrophy (ALD)
September 27, 2021
From
Poxel SA
Via
Business Wire
Poxel Reports Financial Results for First Half 2021 and Provides a Corporate Update
September 23, 2021
From
Poxel SA
Via
Business Wire
Poxel Completes Enrollment in Phase 2 NASH Trial for PXL065 (DESTINY-1) in Biopsy-Proven Patients
September 21, 2021
From
Poxel SA
Via
Business Wire
Poxel to Host Conference Call for First Half 2021 Financial Results on September 23, 2021
September 14, 2021
From
Poxel SA
Via
Business Wire
Poxel Announces Product Launch in Japan for TWYMEEG® as Treatment for Type 2 Diabetes
September 10, 2021
From
Poxel SA
Via
Business Wire
Poxel Announces Its Participation at Investor and Scientific Conferences in September
September 06, 2021
From
Poxel SA
Via
Business Wire
Poxel Appoints Elizabeth Woo as Senior Vice President, Investor Relations, Public Relations and Corporate Communications, Based in Boston
September 02, 2021
From
Poxel SA
Via
Business Wire
Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2021
July 21, 2021
From
Poxel SA
Via
Business Wire
Poxel Announces New Strategic Direction with Increasing Focus on Rare Metabolic Diseases Following Recent Achievements
July 12, 2021
From
POXEL SA
Via
Business Wire
Poxel Presents Results of Two Clinical Studies on its Direct AMP Kinase Activator, the PXL770, at the International Liver Congress (ILC)™ 2021
June 25, 2021
From
Poxel SA
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.